COCP Cocrystal Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COCP

Price (delayed)

$1.56

Market cap

$15.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.87

Enterprise value

-$8.75M

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. ...

Highlights
Cocrystal Pharma's EPS has soared by 61% YoY and by 7% from the previous quarter
Cocrystal Pharma's net income has soared by 54% YoY
The company's quick ratio has shrunk by 74% YoY and by 48% QoQ
The company's equity fell by 33% YoY and by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cocrystalpharma.com
Peers: MRK USNA NATR JNJ

Key stats

What are the main financial stats of COCP
Market
Shares outstanding
10.17M
Market cap
$15.87M
Enterprise value
-$8.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$17.34M
EBITDA
-$17.16M
Free cash flow
-$14.78M
Per share
EPS
-$1.87
Free cash flow per share
-$1.53
Book value per share
$2.59
Revenue per share
$0
TBVPS
$3.24
Balance sheet
Total assets
$31.26M
Total liabilities
$4.88M
Debt
$1.85M
Equity
$26.38M
Working capital
$25.83M
Liquidity
Debt to equity
0.07
Current ratio
8.92
Quick ratio
8.12
Net debt/EBITDA
1.44
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-52.1%
Return on equity
-56.9%
Return on invested capital
-927.2%
Return on capital employed
-61.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COCP stock price

How has the Cocrystal Pharma stock price performed over time
Intraday
2.63%
1 week
3.31%
1 month
5.41%
1 year
-36.84%
YTD
-9.42%
QTD
11.43%

Financial performance

How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.56M
Net income
-$17.98M
Gross margin
N/A
Net margin
N/A
Cocrystal Pharma's net income has soared by 54% YoY
The operating income has soared by 52% YoY

Growth

What is Cocrystal Pharma's growth rate over time

Valuation

What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
0.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cocrystal Pharma's EPS has soared by 61% YoY and by 7% from the previous quarter
The stock's P/B is 39% below its 5-year quarterly average of 1.0
The company's equity fell by 33% YoY and by 14% QoQ

Efficiency

How efficient is Cocrystal Pharma business performance
COCP's return on invested capital has surged by 76% year-on-year and by 11% since the previous quarter
The ROA has grown by 28% YoY but it has contracted by 7% from the previous quarter
Cocrystal Pharma's ROE has increased by 24% YoY but it has decreased by 10% from the previous quarter

Dividends

What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COCP.

Financial health

How did Cocrystal Pharma financials performed over time
The company's total liabilities has surged by 153% QoQ
The company's quick ratio has shrunk by 74% YoY and by 48% QoQ
The debt is 93% less than the equity
The company's equity fell by 33% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.